相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma
L. C. Krol et al.
EUROPEAN JOURNAL OF CANCER (2012)
Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: may a clinical and pathological model of a patient's qualification for targeted therapy have an impact on time to obtain genetic results?
Marzena Anna Lewandowska et al.
KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2012)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR
Ronald van Eijk et al.
PLOS ONE (2011)
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
Mi Jung Kwon et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice
D. Santini et al.
ANNALS OF ONCOLOGY (2010)
Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations Diagnostic and Clinical Implications
Athanasios C. Tsiatis et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
Vassiliki Kotoula et al.
PLOS ONE (2009)
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Jihye Yun et al.
SCIENCE (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M. Haigis et al.
NATURE GENETICS (2008)
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
J. H. J. M. van Krieken et al.
VIRCHOWS ARCHIV (2008)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers
H Namba et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers
IJ Kim et al.
HUMAN GENETICS (2003)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
